This filing follows the successful completion of a clinical study conducted by the company and the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) of the National Institutes of Health (NIH) under a cooperative research and development agreement (CRADA).
The study assessed HA ELISA test kit as a marker for liver fibrosis in nonalcoholic steatohepatitis patients.
Invasive liver biopsy procedures are being used to diagnose nonalcoholic steatohepatitis patients.
The Corgenix-NIDDK study was focused on developing a non-invasive method of diagnosis.
Nonalcoholic fatty liver disease is a chronic mild liver condition associated with obesity and insulin resistance, characterized by the presence of fat in the liver.
The FDA has yet to evaluate the safety and efficacy of the HA ELISA test kit.